NCT04863105View on ClinicalTrials.gov

Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 24, 2017

Primary Completion Date

December 25, 2017

Study Completion Date

April 9, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)

"Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."

Trial Locations (1)

266003

Phase I Clinical Research Center, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT04863105 - Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter